Aslı Çelebi TAYFUR, Raziye Merve YARADILMIŞ, Fatma ULUS, Aysun Çaltık YILMAZ, Esra ÖZAYAR, Berrin KOŞAR, Bahar BÜYÜKKARAGÖZ, Eyüp HORASANLI

Bismuth intoxication resulting in acute kidney injury in a pregnant adolescent girl

Bismuth intoxication is a rare cause of acute kidney injury (AKI) and isusually reversible by appropriate therapeutic measures. We present here acase of an adolescent pregnant girl who developed AKI due to an overdoseof colloidal bismuth subcitrate (CBS, total amount of 6 g). She receivedparenteral chelating agent dimercaprol for 14 days. Continuous venovenoushemodiafiltration (CVVHD) with high-flux membrane was carried out in thefirst 3 days of chelating therapy and intermittent hemodialysis for 11 days,thereafter. The patient recovered clinically and was discharged after 21 days.She gave birth to a healthy term boy. At the last visit, the baby was 6 monthsold with normal growth and development as well as normal kidney functions.Neither deterioration in renal functions nor emergence of proteinuria wasrecorded in the patient during follow-up care after hospital discharge. In casesof AKI due to an overdose of CBS, treatment with dimercaprol combinedwith high flux hemodiafiltration and subsequently hemodialysis appears tobe both useful and safe for bismuth elimination.

PDF

___

1. Keogan DM, Griffith DM. Current and potential applications of bismuth-based drugs. Molecules 2014; 19: 15258-15297.

2. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11 (Suppl 1): 27-33.

3. Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36: 132-157.

4. Bradley B, Singleton M, Li Wan Po A. Bismuth toxicity-a reassesment. J Clin Pharm Therapeut 1989; 14: 423-441.

5. Sun H, Li H, Mason AB, Woodworth RC, Sadler PJ. Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem 2001; 276: 8829-8835.

6. Sun H, Szeto KY. Binding of bismuth to serum proteins: implication for targets of Bi(III) in blood plasma. J Inorg Biochem 2003; 94: 114-120.

7. Erden A, Karahan S, Bulut K, et al. A case of bismuth intoxication with irreversible renal damage. Int J Nephrol Renovasc Dis 2013; 6: 241-243.

8. Cengiz N, Uslu Y, Gök F, Anarat A. Acute renal failure after overdose of colloidal bismuth subcitrate. Pediatr Nephrol 2005; 20: 1355-1358.

9. Serfontein WJ, Mekel R. Bismuth toxicity in man II. Review of bismuth blood and urine levels in patients after administration of therapeutic bismuth formulations in relation to the problem of bismuth toxicity in man. Res Commun Chem Pathol Pharmacol 1979; 26: 391-411.

10. Leussink BT, Slikkerveer A, Krauwinkel WJ, et al. Bismuth biokinetics and kidney histopathology after bismuth overdose in rats. Arch Toxicol 2000; 74: 349-355.

11. Hruz P, Mayr M, Low R, Drewe J, Huber G. Fanconi’s syndrome, acute renal failure, and tonsil ulcerations after colloidal bismuth subcitrate intoxication. Am J Kidney Dis 2002; 39: E18.

12. Boertz J, Hartmann LM, Sulkowski M, et al. Determination of trimethylbismuth in the human body after ingestion of colloidal bismuth subcitrate. Drug Metab Dispos 2009; 37: 352-358.

13. Nenov VD, Marinov P, Sabeva J, Nenov DS. Current applications of plasmapheresis in clinical toxicology. Nephrol Dial Transplant 2003; 18 (Suppl 5): v56-v58.

14. Disel NR, Açikalin A, Sebe A, Gokel Y. Utilization of plasmapheresis in the management of bismuth intoxication with acute renal failure. Saudi J Kidney Dis Transpl 2017; 28: 629-632.

15. Mirrakhimov AE, Barbaryan A, Gray A, Ayach T. The role of renal replacement therapy in the management of pharmacologic poisonings. Int J Nephrol 2016; 2016: 3047329.

16. Işlek I, Uysal S, Gök F, Dündaröz R, Küçüködük S. Reversible nephrotoxicity after overdose of colloidal bismuth subcitrate. Pediatr Nephrol 2001; 16: 510-514.

17. Elmas AT, Tabel Y. Acute kidney injury associated with rapid treatment of hemodiafiltration for bismuth intoxication: Update and review of the literature. J Turgut Ozal Med Cent 2013; 20: 344-347.

18. Oshvandi K, Kavyannejad R, Borzuo SR, Gholyaf M. High-flux and low-flux membranes: efficacy in hemodialysis. Nurs Midwifery Stud 2014; 3: e21764.

19. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131: 283-311.

20. Slikkerveer A, Noach LA, Tytgat GN, Van der Voet GB, De Wolff FA. Comparison of enhanced elimination of bismuth in humans after treatment with meso-2,3- dimercaptosuccinic acid and D,L-2,3-dimercaptopropane1-sulfonic acid. Analyst 1998; 123: 91-92.

21. Vilensky JA, Redman K. British anti-Lewisite (dimercaprol): an amazing history. Ann Emerg Med 2003; 41: 378-383.

22. Gomez M, Sanchez DJ, Colomina MT, Domingo JL, Corbella J. Evaluation of the protective activity of BAL (2,3-dimercaptopropanol) and DMPS (sodium 2,3-dimercaptopropane-1-sulfonate) on methylmercuryinduced developmental toxicity in mice. Arch Environ Contam Toxicol 1994; 26; 64-68.

23. Domingo JL. Developmental toxicity of metal chelating agents. Reprod Toxicol 1998; 12: 499-510.

24. Vale JA, Kulig K; American Academy of Clinical Toxicology;European Association of Poison Centres and Clinical Toxicologists. Position paper: gastric lavage. J Toxicol Clin Toxicol 2004; 42: 933-943.

25. Večera R, Ondra P, Jezdinský J, Adamus M. Gastric lavage after peroral intoxication--controversial views. Cas Lek Cesk 2015; 154: 174-175.